IL-2 Conjugates With IL-2Rβγ Bias for Safer Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IL-2 therapies for cancer treatment are limited by severe side effects and inefficiencies due to the pleiotropic nature of interleukin-2, which induces both immune stimulatory and suppressive T cell responses, and the challenge of maintaining effective antitumor immunity without systemic vascular leak syndrome.
Innovation Solution
Development of IL-2 conjugates with a biased affinity for IL-2Rβγ, featuring a linker and spacer moiety, to enhance immune activation while minimizing IL-2Rαβγ interaction, combined with additional immune agonists to boost effector T cells and NK cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose IL-2 is administered to stimulate antitumor efficacy, then immune response is enhanced, but severe side effects occur including cardiovascular, pulmonary, hepatic, gastrointestinal, neurologic and hematological toxicity
Solution Approach 1:
The patent applies local quality by creating IL-2 conjugates with biased affinity that concentrate immune-stimulating activity at the tumor site while minimizing systemic exposure. The conjugate structure enables selective accumulation in tumor tissue through EPR effect and active targeting, providing high local concentration of IL-2 activity where needed while reducing systemic toxicity
Solution Approach 2:
The patent uses targeted delivery systems and conjugates as intermediaries between IL-2 and tumor cells. These intermediaries include antibody-IL-2 conjugates, nanoparticle-IL-2 complexes, and peptide-IL-2 conjugates that mediate selective delivery to tumor cells expressing specific surface markers, thereby enhancing antitumor efficacy while reducing off-target toxicity
2Reliability
If IL-2 is administered to activate effector T cells, then antitumor immunity is enhanced, but T regulatory cells outcompete effector T cells for IL-2 binding when IL-2 levels drop, limiting anti-tumor immunity
Solution Approach 1:
The patent creates conjugates with biased affinity that preferentially bind to IL-2 receptors on effector T cells and NK cells while having reduced affinity for T regulatory cell receptors. This local quality differentiation ensures that IL-2 activity is directed toward anti-tumor effector cells even when overall IL-2 levels are low, preventing Treg outcompetition
Solution Approach 2:
The patent employs partial action by using sub-optimal doses of IL-2 in combination with targeted delivery systems. The conjugates provide sufficient IL-2 activity at the tumor site to activate effector cells without achieving systemic concentrations that would trigger Treg outcompetition, thereby maintaining immune response balance
3Reliability
If IL-2 conjugates with biased affinity for IL-2Rβγ are developed, then immune activation is enhanced while IL-2Rαβγ interaction is minimized, but conjugate complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the IL-2 molecule into separate functional components: a targeted delivery moiety (antibody, nanoparticle, or peptide) and the IL-2 cytokine portion. This segmentation allows independent optimization of targeting specificity and immune activation, achieving biased affinity while managing structural complexity through modular design
Solution Approach 2:
The patent uses composite materials by combining IL-2 with targeting moieties to create conjugates with tailored properties. The composite structure integrates the immune-stimulating properties of IL-2 with the selective targeting capabilities of antibodies, peptides, or nanoparticles, achieving biased affinity through compositional design rather than complex structural modifications
Data Source
AI summary
The present invention relates to IL-2 conjugates, a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such IL-2 conjugate or a pharmaceutically acceptable salt thereof and their uses.